What is a genomic test?
A genomic test examines the activity and interaction of genes within a sample of tumor tissue. The Oncotype DX Genomic Prostate Score (GPS) is a genomic test, which can help determine how aggressive your cancer is.
What is active surveillance?
Active surveillance is a management plan for carefully monitoring the cancer in your prostate without treatment. Under active surveillance, you’ll have regular check-ups and ongoing testing, typically including
- Checking prostate-specific antigen (PSA) levels.
- Regular digital rectal exams.
- Repeat biopsy as your doctor recommends.
Even with close monitoring via active surveillance, cancer might eventually progress. If your doctor observes any changes in your tumor, you might be advised to receive treatment.
When should the Oncotype DX GPS test be used?
If you are a man who has been recently diagnosed with NCCN very low, low or select cases of intermediate-risk prostate cancer, and have not yet begun treatment with surgery or radiation therapy, the Oncotype DX GPS test might be appropriate for you. The GPS test isn’t appropriate for those with advanced prostate cancer. The test can only be ordered by a licensed healthcare professional. See if the Oncotype DX GPS might be right for you.
Does the Oncotype DX GPS test replace other lab tests?
No. The results of the Oncotype DX GPS test are intended to be used together with the results of other tests that are performed to evaluate prostate cancer. These include PSA level, Gleason score, and clinical assessment of tumor stage.
How long does it take to get the results?
Once Genomic Health receives the sample of your biopsy from your pathologist, it usually takes about two weeks for the results to be available. The Oncotype DX GPS report is sent to your doctor and/or the pathologist who submitted your tissue sample. Once they receive the report, they will contact you to discuss the results and treatment recommendations.
Is the Oncotype DX Genomic Prostate Score test covered by insurance?
The Oncotype DX GPS test is covered by Medicare for NCCN very low and low risk disease. Private insurance coverage varies. To help you navigate insurance and other payment options for Oncotype DX testing, Genomic Health offers the Genomic Access Program (GAP). This program can help you determine if you have coverage, and if so, to secure reimbursement. If you don’t have coverage for testing, GAP will work with you to make an appeal and/or provide financial assistance when possible.
Below are videos that can help you learn more about prostate cancer and personalizing treatments with Oncotype DX Genomic Prostate Score.
If you have questions about this test and would like to speak with a knowledgeable Customer Service specialist at Genomic Health, please contact us.
Your Oncotype DX Genomic Prostate Score Can Help You Navigate Through Your Treatment Options
Your Oncotype DX Genomic Prostate score will arm you with information that'll help you take charge of your cancer treatment decision with confidence.